Guggenheim raised the firm’s price target on Tenet Healthcare (THC) to $238 from $221 and keeps a Buy rating on the shares, stating that the company “once again delivered a solid core quarter.” Tenet’s high-acuity strategy and approach to expectations still suggests more EBITDA, multiple expansion, and ultimately potential share price upside, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare Reports Strong Q3 2025 Results
- Strong Performance and Strategic Growth Drive Buy Rating for Tenet Healthcare
- Tenet Healthcare price target raised to $230 from $225 at BofA
- Morning Movers: UPS and PayPal jump following quarterly reports
- Tenet Healthcare reports Q3 adjusted EPS $3.70, consensus $3.35